Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.

ABSTRACT:

Objective

To identify which factors influence humoral response to coronavirus disease 2019 (COVID-19) vaccination in rituximab (RTX)-treated patients.

Methods

This was an observational, prospective, usual care study including consecutive patients with inflammatory rheumatic diseases in maintenance therapy with RTX. All patients received a two-dose regimen COVID-19 vaccination. Serum IgG antibody levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins were measured at the time of the new RTX infusion.

Results

From the recruited patients, 16/45 (36%) produced antibodies reaching the assay cut-off value of 15 AU/ml and 29/45 (64%) had a negative serology. Within RTX-treated patients, 25 (56%) had undetectable B cells. Negative serology

SUBMITTER: Avouac J 

PROVIDER: S-EPMC8689920 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature